2
•
Incidence 2–7% of patients with
advanced NSCLC
•
Age: 50–60 years
•
Light/never smoker
•
Brain metastases (>50%) during
the course of the disease
•
Predominantly
adenocarcinoma histology
(signet cell)
•
Testing
ALK
+ NSCLC
•
De Castro, et al. Clin and Trasl 2013; Gridelli, et al. Cancer Treat Rev 2014; Shaw, et al. Cin Cancer Res 2011
•
Dearden, et al. Ann Oncol 2013; Hallberg, et al. Nat Rev Cancer 2013; Rikova, et al. Cell 2007
Soda, et al. Nature 2007; Perez, et al. Lung Cancer 2014; Shaw, et al. WCLC 2015; Ou, et al. ASCO 2015; Mok, et al. ASCO 2015
